Related Experiment Videos
Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases
M Tsujisaki1, K Imai, H Hirata
1Department of Internal Medicine, Sapporo Medical College, Japan.
Clinical and Experimental Immunology
|July 1, 1991
Summary
A novel immunoassay detects soluble intercellular adhesion molecule-1 (ICAM-1) in patient sera. Elevated ICAM-1 levels correlate with malignant diseases, suggesting its potential as a tumor burden marker.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Intercellular adhesion molecule-1 (ICAM-1) plays a role in immune cell adhesion.
- Soluble ICAM-1 (sICAM-1) may serve as a biomarker in various diseases.
Purpose of the Study:
- To develop a sensitive assay for detecting shedding ICAM-1 antigen.
- To evaluate the potential of serum ICAM-1 as a tumor burden marker.
Main Methods:
- Preparation of a new monoclonal antibody (MoAb) HA58 targeting the ICAM-1/LFA-1 binding site.
- Establishment of a double-determinant immunoassay (DDIA) using MoAb HA58 and MoAb CL207.
- Induction of ICAM-1 expression and shedding by human recombinant interferon-gamma (IFN-γ) in a dose- and time-dependent manner.
Main Results:
- DDIA successfully detected shedding ICAM-1 antigen in human sera.
- Higher incidence of positive ICAM-1 antigen in malignant diseases compared to benign diseases or healthy controls.
- Elevated serum ICAM-1 levels observed in cancer patients with liver metastasis.
Conclusions:
- Serum ICAM-1 antigen is a potential biomarker for monitoring tumor burden in cancer patients.
- The developed DDIA is a valuable tool for sICAM-1 detection.